Vaxcyte (NASDAQ:PCVX) COO Sells $121,185.00 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX) COO Jim Wassil sold 2,250 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $53.86, for a total transaction of $121,185.00. Following the sale, the chief operating officer owned 157,541 shares in the company, valued at approximately $8,485,158.26. The trade was a 1.41% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jim Wassil also recently made the following trade(s):

• On Wednesday, July 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The shares were sold at an average price of $56.33, for a total transaction of $126,742.50.
• On Monday, June 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The stock was sold at an average price of $49.52, for a total transaction of $111,420.00.

Vaxcyte Price Performance

Shares of NASDAQ PCVX opened at $58.07 on Friday. The firm has a fifty day moving average price of $53.85 and a 200-day moving average price of $55.21. The stock has a market cap of $8.39 billion, a PE ratio of -7.61 and a beta of 1.23. Vaxcyte, Inc. has a 1 year low of $29.29 and a 1 year high of $65.00.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.97) EPS for the quarter, beating the consensus estimate of ($2.06) by $0.09. During the same quarter in the prior year, the company earned ($1.22) EPS. On average, research analysts expect that Vaxcyte, Inc. will post -7.91 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have issued reports on PCVX. Zacks Research lowered shares of Vaxcyte from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 14th. Wall Street Zen raised shares of Vaxcyte from a “strong sell” rating to a “sell” rating in a report on Saturday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a research report on Monday, July 6th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $86.00.

Institutional Investors Weigh In On Vaxcyte

Large investors have recently made changes to their positions in the company. Smartleaf Asset Management LLC boosted its stake in Vaxcyte by 156.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock valued at $27,000 after buying an additional 364 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its holdings in Vaxcyte by 1,463.4% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company’s stock valued at $30,000 after buying an additional 600 shares in the last quarter. EverSource Wealth Advisors LLC increased its stake in Vaxcyte by 33.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock worth $34,000 after acquiring an additional 184 shares during the last quarter. CIBC Private Wealth Group LLC increased its stake in Vaxcyte by 22,500.0% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,356 shares of the company’s stock worth $49,000 after acquiring an additional 1,350 shares during the last quarter. Finally, Capital Advisors Ltd. LLC purchased a new stake in shares of Vaxcyte during the 1st quarter worth approximately $58,000. 96.78% of the stock is owned by institutional investors.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.